KR20100022309A - Composition for preventing and treating acne comprising bacteriocin derived from enterococcus faecalis sl-5 - Google Patents

Abstract

The present invention relates to a novel use of bacteriocin derived from Enterococcus facules SL-5, and more particularly, to prevent and treat acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, which is a bacteriocin derived from Enterococcus faculis SL-5. It relates to a composition for. The present invention provides a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 produced by Enterococcus faculis SL-5 exhibiting excellent antibacterial activity against propionibacterium acne, the causative agent of acne. The polypeptide of the present invention shows excellent antimicrobial activity against propionibacterium acne, which is a causative agent of acne, and thus inhibits their growth, and thus can be used for the prevention, treatment and improvement of acne.

Description

Composition for preventing and treating acne comprising bacteriocin derived from Enterococcus faecalis SL-5}

The present invention relates to a novel use of bacteriocin derived from Enterococcus facules SL-5, and more particularly, to prevent and treat acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, which is a bacteriocin derived from Enterococcus faculis SL-5. It relates to a composition for.

In general, acne is known to be caused by inflammatory reactions caused by the stimulation of free fatty acids and various low molecular substances produced by the lipase of the anaerobic dermatitis propionibacterium acne. Drugs in the form of oral or external preparations have been used for the treatment of acne, for example, anti-inflammatory effects of sebum production inhibitors, steroid hormones and nonsteroidal anti-inflammatory analgesics using anti-male hormones, Antibacterial agents such as sochinol, sulfur, salicylic acid, benzoyl peroxide, retinoic acid or isotretinoin and keratin release agents, antibiotics such as tetracycline, erythromycin, and macrocycline to inhibit the activity of propionibacterium acinis have. On the other hand, recently, a method using azelaic acid has also been used a lot.

However, the methods described above have some results in acne treatment, but have some problems in terms of usability. In other words, the use of hormones has been reported to inhibit the growth of the epidermis and other hormone abuse side effects, keratin release agents such as retinoic acid and benzoyl peroxide may cause skin irritation and contact dermatitis due to exfoliation, tetracycline Such antibiotics are known for the emergence of resistant bacteria and for the possibility of photosensitivity. In particular, isotretinoin is known to have a teratogenic effect on the fetus.

Therefore, the necessity of developing a product that is safe for the human body and has excellent acne treatment effect in acne skin is steadily emerging.

On the other hand, lactic acid bacteria (lactic acid bacteria) is a microorganism that produces lactic acid by using carbohydrate anaerobic and is widely distributed in nature. This microorganism has been used as a means of preserving food in both East and West by suppressing the growth of decaying microorganisms that grow well in neutral and alkaline, and especially in the processing of milk, dairy products, meat products, vegetables, and various salted fish. . Lactic acid bacteria improve the preservation of foods by reducing their pH by their various metabolites, organic acids, such as lactic acid and acetic acid, because they have bactericidal action against most microorganisms. In addition to organic acids, hydrogen peroxide and the bacteriocins they produce are involved in preservation.

Bacteriocin is a protein or protein-based antimicrobial substance produced by bacteria. Generally, bacteriocin is a general antibiotic substance because it shows a narrow antimicrobial range limited to strains that are lineage and lineage similar to the antimicrobial strains themselves. It is a natural antimicrobial protein that is distinguished from. Bacteriocin is produced by lactic acid bacteria that are commonly found in various fermented foods and consumed through daily diets. Unlike conventional antibiotics, the bacteriocin is broken down by protein hydrolase of the digestive system as soon as it is ingested by the human body. In view of non-toxicity and non-persistence in human body, it is expected to be useful as a new biopreservative of food or biocontrol agent of fermented food. Nisin, the most widely known bacteriocin produced by lactic acid bacteria, has long been commercially available due to its broad antimicrobial range, and in the United States, the Food and Drug Safety Administration (FDA) in 1988 identified GRAS (Generally Recognized as Safe) food additives. Admitted to.

The inventors of the present invention, while studying the antimicrobial activity of Enterococcus facules SL-5, and found that there is an excellent antimicrobial activity against the acne-related bacterium propiobacterium acnes, the polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 By confirming the excellent antimicrobial activity against Propiobacterium acnes was completed the present invention by developing a composition for preventing and treating acne comprising the polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient.

Accordingly, it is an object of the present invention to provide novel uses of the polypeptides of SEQ ID NO: 1 or SEQ ID NO: 2.

In order to achieve the above object, the present invention provides a composition for preventing and treating acne comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient.

In order to achieve the another object of the present invention, the present invention provides a composition for antibacterial against Propionibacterium acnes comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient to provide.

In order to achieve another object of the present invention, the present invention inhibits the growth of Propionibacterium acnes comprising the step of applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 Provide a way to.

Hereinafter, the content of the present invention will be described in more detail.

The composition of the present invention is characterized in that it comprises a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient.

In one embodiment of the present invention, the antimicrobial activity spectrum of Enterococcus facules SL-5 was confirmed, and it was confirmed that the antimicrobial activity against propionibacterium acne is a cause of acne.

In addition, in another embodiment of the present invention, by partially purifying the material showing antimicrobial activity, the N-terminal sequence was identified, and the peptide showing the antimicrobial activity was separated by PCR. As a result, it was confirmed that the polypeptide having a nucleotide sequence of SEQ ID NO: 1 and SEQ ID NO: 2.

Peptides of the invention can be prepared by chemical synthesis (Creighton, Proteins; Structures and Molecular Principles, WH Freeman and Co., NY, 1983) known in the art. Representative methods include, but are not limited to, liquid or solid phase synthesis, fragment condensation, F-MOC or T-BOC chemistry (Chemical Approaches to the Synthesis of Peptides and Proteins, Williams et. al ., Eds., CRC Press, Boca Raton Florida, 1997; A Practical Approach, Athert on & Sheppard, Eds., IRL Press, Oxford, England, 1989).

In addition, the peptide of the present invention can be prepared by genetic engineering methods. First, a DNA sequence encoding the peptide is constructed according to a conventional method. DNA sequences can be constructed by PCR amplification using appropriate primers. Alternatively, DNA sequences may be synthesized by standard methods known in the art, such as using automated DNA synthesizers (such as those sold by Biosearch or Applied Biosystems). The constructed DNA sequence is a vector comprising one or more expression control sequences (e.g., promoters, enhancers, etc.) that are operatively linked to this DNA sequence to regulate expression of the DNA sequence. The host cell is transformed with the recombinant expression vector formed therefrom. The resulting transformants are cultured under appropriate media and conditions to allow the DNA sequence to be expressed, to recover substantially pure peptides encoded by the DNA sequences from the culture. The recovery can be carried out using methods known in the art (eg chromatography). By "substantially pure peptide" it is meant that the peptide according to the invention is substantially free of any other protein derived from the host. For genetic engineering methods for peptide synthesis of the present invention, reference may be made to Maniatis et. al ., Molecular Cloning; A laboratory Manual, Cold Spring Harbor laboratory, 1982; Sambrook et al ., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, Second (1998) and Third (2000) Edition; Gene Expression Technology, Method in Enzymology, Genetics and Molecular Biology, Method in Enzymology, Guthrie & Fink (eds.), Academic Press, San Diego, Calif, 1991; And Hitzeman et al ., J. Biol. Chem., 255: 12073-12080, 1990.

On the other hand, since the polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 inhibits the growth of propionibacterium acne, the present invention is a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 It provides a composition for antibacterial to Propionibacterium acnes (Propionibacterium acnes) comprising.

In addition, the composition of the present invention comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient may be provided in the form of a product. The product may be a cosmetic or a medicament.

For pharmaceuticals, the compositions of the present invention may further contain one or more pharmaceutically acceptable carriers, excipients or diluents. Pharmaceutically acceptable carriers may further include, for example, carriers for parenteral administration. Carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Other pharmaceutically acceptable carriers may be referred to those described in the following documents (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

Medicines comprising the compositions of the invention can be administered to any mammal, including humans. Preferably the composition of the present invention may be administered transdermally. As used herein, 'transdermal administration' refers to the administration of the composition of the present invention to cells or skin so that the active ingredient is delivered into the skin. For example, the composition of the present invention may be prepared into an injectable formulation and administered by lightly pricking the skin with a 30 gauge thin injection needle, or by applying it directly to the skin.

The pharmaceutical composition of the present invention may be formulated according to the route of administration as described above. For example, formulations for parenteral administration may be formulated by methods known in the art in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols and nasal inhalants. These formulations are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a prescription generally known in all pharmaceutical chemistries.

The total effective amount of a polypeptide of the invention can be administered to a patient in a single dose and can be administered by a fractionated treatment protocol that is administered in multiple doses for long periods of time. The composition of the present invention may vary the content of the active ingredient depending on the extent of the disease. The dose is determined by taking into consideration the various factors such as the age, weight, health condition, sex, severity of the disease, diet and excretion rate, as well as the route of administration and the number of treatments of the composition. Given this, one of ordinary skill in the art will be able to determine the appropriate effective dosage and preferably be 0.001 μg / kg body weight to 10 mg / kg body weight. The product comprising the composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is exhibited.

In the case of cosmetics, the polypeptides of the invention can also be prepared in any form of formulation suitable for topical application according to methods known in the art by further containing cosmetically and / or dermatologically acceptable excipients. For example, but not limited to, the cosmetic composition according to the invention may be a solution, gel, solid, emulsion, suspension, microemulsion, microcapsules, microgranules, ionic and / or nonionic vesicle dispersants, creams, skins, It may be prepared in the form of a lotion, powder, ointment, spray or stick.

Such cosmetically and / or dermatologically acceptable excipients may include emollients, emulsifiers, thickening agents and solvents.

The emollients are used to soften, sooth, coat, smooth or moisturize the skin. In the present invention, the emollient may use all kinds known in the art and may be, for example, petroleum based, fatty acid esters, alkyl ethoxylates, fatty acid ester ethoxylates, fatty alcohols, polysiloxanes or mixtures thereof. In addition to propylene glycol, butylene glycol, glycerin, triethylene glycol, mercury, waxes, fatty acids, fatty alcohol ethers, glycerides, acetoglycerides, ethoxylated glycerides, other fatty acid esters of polyhydroxy alcohols, lanolin and derivatives thereof Such conventional emollients.

The emulsifier serves to mix the water phase and the oil phase of the cosmetic composition. In the present invention, the emulsifier may optionally contain one or more, and may include both nonionic, anionic or cationic. The type of the emulsifier may be determined depending on whether the emulsion is in water-in-oil dispersion or oil-in-water dispersion. Examples of suitable emulsifiers include, but are not limited to, sorbitan trioleate, sorbitan tristearate, glycerol monooleate, glycerol monostearate, glycerol monolaurate, sorbitan sesquioleate, sorbitan monooleate, Sorbitan monostearate, polyoxyethylene stearyl ether, polyoxyethylene sorbitol beeswax derivative, PEG 200 dilaurate, PEG 200 monostearate, PEG 400 dioleate, sorbican monopalmitate, polyoxyethylene monostearate and Polyoxyethylene sorbitan monostearate and the like.

Thickeners include crosslinked carboxypolymethylene polymers, ethyl cellulose, polyethylene glycol, tracant gum, karaya gum, xanthan gum, bentonite, hydroxyethyl cellulose and hydroxypropyl cellulose.

As the solvent, purified water, alcohol or a mixture of purified water and alcohol may be used.

Examples of other optional cosmetic additives that may optionally be used include, but are not limited to, preservatives such as para-hydroxybenzoate esters, butyl hydroxy toluene, ascorbic acid and its derivatives and antioxidants such as tocopherol and its derivatives, glycerol, Wetting agents such as sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, pH buffers such as acetates, phosphates, citrate, triethanolamine and carbonates, waxes such as beeswax, paraffin Types, thickeners, activity enhancers, colorants and flavorings can be used.

On the other hand, since the polypeptide of the present invention inhibits the growth of propionibacterium acne, the present invention comprises the step of applying a propionibacterium acne comprising applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 It provides a method of inhibiting the growth of propionibacterium acnes).

Accordingly, the present invention provides a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 produced by Enterococcus faculis SL-5, which exhibits excellent antibacterial activity against propionibacterium acne, the causative agent of acne. The polypeptide of the present invention shows excellent antimicrobial activity against propionibacterium acne, which is a causative agent of acne, and thus inhibits their growth, and thus can be used for the prevention, treatment and improvement of acne.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

< Example  1>

Confirmation of Cell Culture and Antibacterial Spectrum

<1-1> Cell Culture

Enterococcus Facules SL-5 ( Enterococcus faecalis SL-5, 16s rRNA sequence according to GenBank Accession No. AY692453) was inoculated in MRS liquid medium and incubated for about 16 hours under anaerobic conditions substituted with nitrogen gas at 37 ° C. Propionibacterium acnes ( ATCC 29399) was used as a test strain in RCM broth (reinforced clostridial medium broth, Merck, Darmstadt, Germany), Bacillus subtilis ( Bacillus) subtilis , KFRI 179), Bacillus cereus ( KCTC 3624) and Staphylococcus aureus (KCTC 1972) Escherichia coli O157, Listeria monocytogenes, Salmonella paratypy A, Shigella flexneri Incubated for about 16 hours at 37 ℃ in a BHI broth (brain heart infusion broth).

<1-2> Enterococcus Facules SL -5 antimicrobial activity spectrum

Cell cultures of E. faecalis SL-5 were removed by centrifugation (9,940 xg, 15 min, 4 ° C), and the remaining cells were further filtered (membrane pore size, 0.45 ㎛). The component was completely removed. The supernatant component thus obtained was named 'fermentation filtrate'. The antimicrobial activity of the fermentation filtrate was measured by the 'spot-on-the-lawn' method (Van Reenen et al . , 2006, Appl . Environ . Microbiol . 72: 7644-7651). The fermentation filtrate was used by diluting it sequentially in anaerobic water (42.3 mM Na ₂ HPO ₄ , 33.1 mM KH ₂ PO ₄ , 0.05% (v / v) Tween 80, 3.2 mM L-cystein · HCl, pH 7.0). In addition, 10 μl of the diluted solution was added to an MRS agar plate containing a test strain, and then cultured at 37 ° C. to determine the activity of the clear zone around the drop position.

As a result, as shown in Figure 1 and Table 1, Enterococcus faculis SL-5 is Bacillus cereus KCTC 3624, Bacillus subtilis KFRI 179, Listeria monocytogenes, Propionibacterium acne ATCC 29399 and Staphylo It was shown to have antimicrobial activity against Gram-positive taxa such as Caucasus aureus KCTC 1927, and no antimicrobial activity against Escherichia coli O157, Shigella flexneri and Salmonella paratyp A.

bacteria Inhibition Bacillus cereus KCTC 3624 + Bacillus subtilis KFRI 179 + Esherichia coli O157 - Listeria monocytogenes + Propionibacterium acnes ATCC 29399 + Salmonella paratyphi A - Shigella flexneri - Staphylococcus aureus KCTC 1927 +

< Example  2>

Identification of antimicrobial active substances

<2-1> Partial Purification of Antimicrobial Active Substances

Partial purification was performed to identify substances that exhibit antimicrobial activity. Enterococcus paculis SL-5 was inoculated in 100 ml of MRS medium and incubated for 16 hours at 37 ° C., then inoculated in fresh 2 liters of MRS medium for 8 hours to prepare a fermentation filtrate as in Example 1.

In order to fractionate the fermentation filtrate, ammonium sulfate was added to a final concentration of 70%, and slowly dissolved, followed by centrifugation (20,000 × g / 30 min / 4 ° C.) to obtain a precipitate. The precipitate was dissolved in a standard buffer solution (50 mM Tris-HCl, pH 7.0) to a final volume of 70 ml, and then used a dialysis tubing (MW cut-off of 500 dalton) to remove salts. Was dialyzed three times in standard buffer solution for 48 hours. Ultrafiltration (MW cut-off of 3,000 dalton) was performed to concentrate the dialysate, and 8 ml of the concentrate (7 mg / ml) was added to the CM Sepharose ^TM Fast Flow column (GE Healthcare), a type of liquid chromatography. Fractionation. Fractionation was through a gradient of NaCl concentration from 0 M to 1 M and antimicrobial activity against Propionibacterium acne was detected around 0.5 M NaCl concentration. Among the fractions with antimicrobial activity, the fraction with the maximum activity was analyzed by 16% SDS-Tricine gel electrophoresis, and as shown in FIG. 2A, most proteins were found to be distributed near 5 kDa.

<2-2> Identification of Antimicrobial Active Substances

In Example <1-2> using a duplicate gel for the gel used in Figure 2A to determine whether the protein of about 5 kDa size shows antimicrobial activity against propionibacterium acne The active staining experiment was performed as

As a result, as shown in Fig. 2B, a clear zone is formed in the 5 kDa protein portion that inhibits Propionibacterium acne, indicating that the protein has antimicrobial activity against Propionibacterium acne. Could.

<2-3> Sequence Analysis of Antimicrobial Active Materials

The 5 kDa size protein portion was transferred to a PVDF membrane (polyvinylidene fluoride membrane) to determine the amino acid sequence of the substance in Example <2-2>. The bacteriocin band was cut out of the protein band on the PVDF membrane and 10 N-terminal amino acid sequences were determined using an automatic protein sequence analyzer.

As a result, it was found that the protein had a sequence of Met-Gly-Ala-Ile-Ala-Lys-Leu-Val-Ala-Lys from the N terminus.

The determined amino acid sequences were compared with the proteins present in the National Center for Biotechnology Information (NCBI) protein database using the Basic Alignment Search Tool (BLAST). Enterocin MR10A and B (Mart et al . , 2006, Appl . Environ. Microbiol . 72 : 4245-4249), enterocin L50A (Cintas et al., 1998, J. Bacteriol. 180: 1988-1994) and 100% identity and enterocin L50B (Cintas et al., 1998, J. Bacteriol . 180: 1988-1994). And showed 90% identity. Since Enterocin MR10A and B are considered variants of enterocin L50, based on the nucleotide sequence of enterocin L50, SEQ ID NO: 6 (5'-ATGGGAGCAATCGCAAAATTAGTA-3 ') and SEQ ID NO: 7 (5'-TTAATGTCTTTTTAGCCATTTTTCAATTTGATCTATTGT-3') After the PCR primers were synthesized, PCR was performed using the entire DNA of Enterococcus facules SL-5 as a template to obtain a PCR product consisting of 287bp. The PCR product was determined by determining the total base sequence (SEQ ID NO: 5). Using the determined nucleotide sequence, the alignment of enterocin MR10 and enterocin L50 showed 100% identity with open reading frame (ORF) of enterocin MR10. The structure of Enterococcus faculis SL-5 revealed through the two ORFs are arranged in tandem, so that the SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

In summary, the bacteriocin of Enterococcus facules SL-5 of the present invention showed the same or higher identity as enterocin MR10 or L50, but it had an excellent antimicrobial activity against propionibacterium acne.

As described above, the present invention provides Enterococcus faculis SL-5 and the polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 produced by the microorganism showing excellent antibacterial activity against propionibacterium acne, which is a causative agent of acne. do. Therefore, the polypeptide of the present invention and Enterococcus facules SL-5 show excellent antimicrobial activity against propionibacterium acne, which is a causative agent of acne, thus inhibiting their growth and thus can be used for the prevention, treatment and improvement of acne. .

Figure 1 shows the antimicrobial activity of Enterococcus facules SL-5 (A: Propionibacterium acne ATCC 29399; B: Bacillus subtilis KFRI 179; C: Bacillus cereus KCTC 3624; D: Staphylococcus Aureus KCTC 1927

Figure 2 shows the antibacterial activity (B) of the bacteriocin partial separation result of the present invention (A) and the propionibacterium acne of the duplicated gel.

<110> CHUNG, Myung-jun <120> Composition for preventing and treating acne configuring          bacteriocin derived from Enterococcus faecalis SL-5 <130> NP08-0093 <160> 7 <170> KopatentIn 1.71 <210> 1 <211> 44 <212> PRT <213> Enterococcus faecalis SL-5 <400> 1 Met Gly Ala Ile Ala Lys Leu Val Ala Lys Phe Gly Trp Pro Ile Val   1 5 10 15 Lys Lys Tyr Tyr Lys Gln Ile Met Gln Phe Ile Gly Glu Gly Trp Ala              20 25 30 Ile Asn Lys Ile Ile Asp Trp Ile Lys Lys His Ile          35 40 <210> 2 <211> 43 <212> PRT <213> Enterococcus faecalis SL-5 <400> 2 Met Gly Ala Ile Ala Lys Leu Val Ala Lys Phe Gly Trp Pro Phe Ile   1 5 10 15 Lys Lys Phe Tyr Lys Gln Ile Met Gln Phe Ile Gly Gln Gly Trp Thr              20 25 30 Ile Asp Gln Ile Glu Lys Trp Leu Lys Arg His          35 40 <210> 3 <211> 135 <212> DNA <213> Enterococcus faecalis SL-5 <400> 3 atgggagcaa tcgcaaaatt agtagcaaag tttggatggc caattgttaa aaagtattac 60 aaacaaatta tgcaatttat tggagaagga tgggcaatta acaaaattat tgattggatc 120 aaaaaacata tttaa 135 <210> 4 <211> 132 <212> DNA <213> Enterococcus faecalis SL-5 <400> 4 atgggagcaa tcgcaaaatt agtagcaaag tttggatggc catttattaa aaaattctac 60 aaacaaatta tgcagtttat cggacaagga tggacaatag atcaaattga aaaatggcta 120 aaaagacatt aa 132 <210> 5 <211> 287 <212> DNA <213> Enterococcus faecalis SL-5 <400> 5 atgggagcaa tcgcaaaatt agtagcaaag tttggatggc caattgttaa aaagtattac 60 aaacaaatta tgcaatttat tggagaagga tgggcaatta acaaaattat tgattggatc 120 aaaaaacata tttaaaaata aggatgtgtt aatgtatggg agcaatcgca aaattagtag 180 caaagtttgg atggccattt attaaaaaat tctacaaaca aattatgcag tttatcggac 240 aaggatggac aatagatcaa attgaaaaat ggctaaaaag acattaa 287 <210> 6 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> primer 1 <400> 6 atgggagcaa tcgcaaaatt agta 24 <210> 7 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> primer 2 <400> 7 ttaatgtctt tttagccatt tttcaatttg atctattgt 39  

Claims (5)

Acne prevention and treatment composition comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient. An antimicrobial composition against Propionibacterium acnes comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient. An article comprising the composition of claim 1. The product according to claim 3, wherein the product is a cosmetic or a medicine. A method of inhibiting the growth of Propionibacterium acnes comprising applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.

Images